Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (211-220 of 333) with videos related to

Pageof 34
Sort By:
The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.
Hepatology (Baltimore, Md.)|April 17, 2024
Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN TrialsMuhammad Atif Zahoor, Joshua B Feld, Hsing-Hua Sylvia Lin, et al.
Gastroenterology|September 22, 2010
S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonrespondersJordan J Feld, Apurva A Modi, Ramy El-Diwany, et al.
Gastroenterology|April 29, 2008
Hepatic involvement and portal hypertension predict mortality in chronic granulomatous diseaseJordan J Feld, Nadeem Hussain, Elizabeth C Wright, et al.
The American Journal of Gastroenterology|February 2, 2023
Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment TrialJordan J Feld, Abdus S Wahed, Michael Fried, et al.
Antiviral Therapy|November 16, 2022
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis BJordan J Feld, Eric Lawitz, Tuan Nguyen, et al.
Journal of Viral Hepatitis|October 27, 2022
Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infectionJulia L Casey, Gregory J Dore, Jason Grebely, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2024
Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation StudyRachel L Epstein, Sarah Munroe, Lynn E Taylor, et al.
Hepatology (Baltimore, Md.)|December 15, 2018
Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus InfectionJordan J Feld, Norah A Terrault, Hsing-Hua S Lin, et al.
Gastroenterology|January 20, 2026
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled TrialGrishma Hirode, Hooman F Zangneh, Orlando Cerocchi, et al.
Pageof 34

Showing results (211-220 of 333) with videos related to

Sort By:
Pageof 34
The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.
Hepatology (Baltimore, Md.)|April 17, 2024
Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN TrialsMuhammad Atif Zahoor, Joshua B Feld, Hsing-Hua Sylvia Lin, et al.
Gastroenterology|September 22, 2010
S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonrespondersJordan J Feld, Apurva A Modi, Ramy El-Diwany, et al.
Gastroenterology|April 29, 2008
Hepatic involvement and portal hypertension predict mortality in chronic granulomatous diseaseJordan J Feld, Nadeem Hussain, Elizabeth C Wright, et al.
The American Journal of Gastroenterology|February 2, 2023
Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment TrialJordan J Feld, Abdus S Wahed, Michael Fried, et al.
Antiviral Therapy|November 16, 2022
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis BJordan J Feld, Eric Lawitz, Tuan Nguyen, et al.
Journal of Viral Hepatitis|October 27, 2022
Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infectionJulia L Casey, Gregory J Dore, Jason Grebely, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2024
Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation StudyRachel L Epstein, Sarah Munroe, Lynn E Taylor, et al.
Hepatology (Baltimore, Md.)|December 15, 2018
Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus InfectionJordan J Feld, Norah A Terrault, Hsing-Hua S Lin, et al.
Gastroenterology|January 20, 2026
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled TrialGrishma Hirode, Hooman F Zangneh, Orlando Cerocchi, et al.
Pageof 34